<DOC>
	<DOCNO>NCT00004376</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate safety efficacy alpha-2 adrenergic agonist guanfacine child adolescent Tourette syndrome chronic tic disorder , attention deficit hyperactivity disorder .</brief_summary>
	<brief_title>Phase III Randomized , Double-Blind , Placebo-Controlled Study Guanfacine Tourette Syndrome Attention Deficit Hyperactivity Disorder</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double-blind study . Patients stratify pubertal status . There 7- 14-day washout placebo prior treatment patient . The first group receive oral guanfacine 3 time day 8 week . The dose gradually increased minimize sedation ; day 14 , patient stabilize dose increase clinically indicate tolerate . The second group receive placebo 3 time day 8 week . Patients either group may treat guanfacine additional 8 week .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Tourette syndrome chronic tic disorder meeting Diagnostic Statistical Manual Mental DisordersIV ( DSMIV ) criteria DSMIV diagnosis attention deficit hyperactivity disorder ( ADHD ) Clinician 's Global Impression ADHD great 4 Hyperactivity Index Conners Parent Teacher Questionnaire standard score 65 high ( 1.5 standard deviation unit ) Prior/Concurrent Therapy At least 2 week since medication tic , ADHD , obsessive compulsive disorder ( 4 week since neuroleptic fluoxetine ) No failure prior guanfacine Patient Characteristics Hepatic : No liver failure Renal : No renal failure Cardiovascular : No hypertension No heart disease Pulmonary : No pulmonary disease Other : No Intelligence Quotient 80 No current DSMIV diagnosis follow : Major depression Bipolar disorder Pervasive developmental disorder Psychotic disorder No seizure disorder No significant medical condition No pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2001</verification_date>
	<keyword>Tourette syndrome</keyword>
	<keyword>neurologic psychiatric disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>